Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

This study is testing whether adding hydroxychloroquine (a drug that blocks a cellular recycling process called autophagy) to a standard treatment regimen — encorafenib and cetuximab or panitumumab — can improve outcomes for people with metastatic colorectal cancer that has a BRAF V600E mutation. **You may be eligible if...** - You are 18 or older - You have stage IV colorectal cancer with a confirmed BRAF V600E mutation - You have received at least one prior chemotherapy or targeted therapy for your cancer - You have not had prior BRAF inhibitor therapy - You have measurable disease and are in good overall health (ECOG 0–1) **You may NOT be eligible if...** - You have not yet had any treatment for your metastatic colorectal cancer - You have already received BRAF inhibitor therapy - Your performance status or organ function does not meet study requirements Talk to your doctor to see if this trial is right for you.